For the quarter ending 2025-09-30, QLGN made $2,190,503 in revenue. -$2,905,615 in net income. Net profit margin of -132.65%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net loss | - | - | -2,646,172 | -1,564,797.75 |
| Deemed dividend arising from preferred stock and warrant down-round provision | 867,796 | 1,586 | 0 | 21,901 |
| Loss on disposal of discontinued operations, net of tax | 0 | 0 | 0 | 25,000 |
| Gain (loss) from discontinued operations | 0 | 0 | 0 | -25,000 |
| (benefit from) provision for income taxes | 0 | 0 | 35 | 1,583.5 |
| General and administrative | 1,891,108 | 1,394,932 | 2,494,532 | 1,051,139.5 |
| Research and development | 105,576 | 17,815 | 33,167 | 299,290.5 |
| Credit loss expense - short-term note receivable | -567,000 | 271,000 | 197,000 | 90,000 |
| Total expenses | 1,429,684 | 1,683,747 | 2,724,699 | 1,440,430 |
| Loss from operations | -1,429,684 | -1,683,747 | -2,724,699 | -1,440,430 |
| Loss on change in fair value of derivative liabilities | 0 | 0 | 0 | 47,767 |
| Loss on issuance of convertible debt | 0 | 91,943 | 0 | 89,569.75 |
| Gain on change in fair value of warrant liabilities | - | 15,974 | 39,224 | 103,952.5 |
| Gain on voluntary conversion of convertible debt into common stock | 0 | 0 | - | 14,002.5 |
| Loss on monthly redemptions of convertible debt into common stock | 0 | 0 | 0 | 52,213 |
| Gain on settlements of accounts payable | 0 | - | - | 87,076.25 |
| Other income, net | 0 | - | - | 486.5 |
| Loss (gain) on change in fair value of warrant liabilities | -148,346 | - | - | - |
| Loss on change in fair value of convertible debt | -197,667 | 37,874 | - | -14,249.25 |
| Interest expense | 455,941 | 106,052 | 73,615 | 227,235.75 |
| Interest income | 193,819 | 142,477 | 112,953 | 32,198.75 |
| Total other expense (income), net | -608,135 | -1,670 | 78,562 | -97,784.25 |
| Loss before (benefit from) provision for income taxes | -2,037,819 | -1,685,417 | -2,646,137 | -1,538,214.25 |
| Net loss from continuing operations | -2,037,819 | -1,685,417 | -2,646,172 | -1,539,797.75 |
| Net loss | -2,037,819 | -1,685,417 | - | -1,564,797.75 |
| Net loss attributable to qualigen therapeutics, inc | -2,905,615 | -1,687,003 | -2,646,172 | -1,586,698.75 |
| Total net loss per common share, basic | -4.68 | -1 | -1.82 | -4.388 |
| Total net loss per common share, diluted | -4.68 | -1 | -1.82 | -4.388 |
| Weighted-average number of shares outstanding, basic | 620,694 | 1,683,881 | 1,456,714 | 90,396.75 |
| Weighted-average number of shares outstanding, diluted | 620,694 | 1,683,881 | 1,456,714 | 90,396.75 |
Qualigen Therapeutics, Inc. (QLGN)
Qualigen Therapeutics, Inc. (QLGN)